Complications with low dose methotrexate in rheumatoid arthritis. 1997

S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
January 1982, The Journal of rheumatology,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
January 1997, Therapie,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
September 1986, Thorax,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
June 1990, Ryumachi. [Rheumatism],
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
October 1988, The Journal of rheumatology,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
January 1980, The Journal of rheumatology,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
March 1985, The New England journal of medicine,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
December 1985, The Journal of rheumatology. Supplement,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
May 1990, The Journal of rheumatology. Supplement,
S Kalke, and C Balakrishnan, and G Mittal, and G Mangat, and V R Joshi
January 2004, The Annals of pharmacotherapy,
Copied contents to your clipboard!